O	0	9	Incidence
O	10	13	and
O	14	18	time
O	19	25	course
O	26	28	of
O	29	39	everolimus
O	39	40	-
O	40	47	related
O	48	55	adverse
O	56	62	events
O	63	65	in
B-eligibility	66	80	postmenopausal
I-eligibility	81	86	women
I-eligibility	87	91	with
I-eligibility	92	99	hormone
I-eligibility	100	108	receptor
I-eligibility	108	109	-
I-eligibility	109	117	positive
I-eligibility	118	126	advanced
I-eligibility	127	133	breast
I-eligibility	134	140	cancer
O	140	141	:
O	142	150	insights
O	151	155	from
O	156	162	BOLERO
O	162	163	-
O	163	164	2
O	164	165	.

O	166	168	In
O	169	172	the
O	173	179	BOLERO
O	179	180	-
O	180	181	2
O	182	187	trial
O	187	188	,
O	189	199	everolimus
O	200	201	(
O	201	204	EVE
O	204	205	)
O	205	206	,
O	207	209	an
O	210	219	inhibitor
O	220	222	of
O	223	232	mammalian
O	233	239	target
O	240	242	of
O	243	252	rapamycin
O	252	253	,
O	254	266	demonstrated
O	267	278	significant
O	279	287	clinical
O	288	295	benefit
O	296	300	with
O	301	303	an
O	304	314	acceptable
O	315	321	safety
O	322	329	profile
O	330	334	when
O	335	347	administered
O	348	352	with
O	353	363	exemestane
O	364	365	(
O	365	368	EXE
O	368	369	)
O	370	372	in
O	373	387	postmenopausal
O	388	393	women
O	394	398	with
O	399	406	hormone
O	407	415	receptor
O	415	416	-
O	416	424	positive
O	425	426	(
O	426	428	HR
O	428	429	(
O	429	430	+
O	430	431	)
O	431	432	)
O	433	441	advanced
O	442	448	breast
O	449	455	cancer
O	455	456	.

O	457	459	We
O	460	466	report
O	467	469	on
O	470	473	the
O	474	483	incidence
O	483	484	,
O	485	489	time
O	490	496	course
O	496	497	,
O	498	506	severity
O	506	507	,
O	508	511	and
O	512	522	resolution
O	523	525	of
O	526	535	treatment
O	535	536	-
O	536	544	emergent
O	545	552	adverse
O	553	559	events
O	560	561	(
O	561	564	AEs
O	564	565	)
O	566	568	as
O	569	573	well
O	574	576	as
O	577	586	incidence
O	587	589	of
O	590	594	dose
O	595	608	modifications
O	609	615	during
O	616	619	the
O	620	628	extended
O	629	635	follow
O	635	636	-
O	636	638	up
O	639	641	of
O	642	646	this
O	647	652	study
O	652	653	.

O	654	662	Patients
O	663	667	were
O	668	678	randomized
O	679	680	(
O	680	681	2
O	681	682	:
O	682	683	1
O	683	684	)
O	685	687	to
O	688	695	receive
B-intervention	696	699	EVE
O	700	702	10
O	703	705	mg
O	705	706	/
O	706	709	day
O	710	712	or
B-control	713	720	placebo
O	721	722	(
O	722	725	PBO
O	725	726	)
O	726	727	,
O	728	732	with
O	733	737	open
O	737	738	-
O	738	743	label
O	744	747	EXE
O	748	750	25
O	751	753	mg
O	753	754	/
O	754	757	day
O	758	759	(
O	759	760	n
O	761	762	=
B-total-participants	763	766	724
O	766	767	)
O	767	768	.

O	769	772	The
O	773	780	primary
O	781	784	end
O	785	790	point
O	791	794	was
B-outcome-Measure	795	806	progression
I-outcome-Measure	806	807	-
I-outcome-Measure	807	811	free
I-outcome-Measure	812	820	survival
O	820	821	.

O	822	831	Secondary
O	832	835	end
O	836	842	points
O	843	851	included
B-outcome-Measure	852	859	overall
I-outcome-Measure	860	868	survival
O	868	869	,
B-outcome-Measure	870	879	objective
I-outcome-Measure	880	888	response
I-outcome-Measure	889	893	rate
O	893	894	,
O	895	898	and
B-outcome-Measure	899	905	safety
O	905	906	.

O	907	913	Safety
O	914	925	evaluations
O	926	934	included
O	935	944	recording
O	945	947	of
O	948	951	AEs
O	951	952	,
O	953	963	laboratory
O	964	970	values
O	970	971	,
O	972	976	dose
O	977	990	interruptions
O	990	991	/
O	991	1002	adjustments
O	1002	1003	,
O	1004	1007	and
O	1008	1013	study
O	1014	1018	drug
O	1019	1035	discontinuations
O	1035	1036	.

O	1037	1040	The
O	1041	1047	safety
O	1048	1058	population
O	1059	1068	comprised
B-total-participants	1069	1072	720
O	1073	1081	patients
O	1082	1083	(
O	1083	1086	EVE
O	1087	1088	+
O	1089	1092	EXE
O	1092	1093	,
B-intervention-participants	1094	1097	482
O	1097	1098	;
O	1099	1102	PBO
O	1103	1104	+
O	1105	1108	EXE
O	1108	1109	,
B-control-participants	1110	1113	238
O	1113	1114	)
O	1114	1115	.

O	1116	1119	The
O	1120	1126	median
O	1127	1133	follow
O	1133	1134	-
O	1134	1136	up
O	1137	1140	was
O	1141	1143	18
O	1144	1150	months
O	1150	1151	.

O	1152	1157	Class
O	1157	1158	-
O	1158	1164	effect
O	1165	1175	toxicities
O	1175	1176	,
O	1177	1186	including
B-outcome	1187	1197	stomatitis
O	1197	1198	,
B-outcome	1199	1210	pneumonitis
O	1210	1211	,
O	1212	1215	and
B-outcome	1216	1229	hyperglycemia
O	1229	1230	,
O	1231	1235	were
O	1236	1245	generally
O	1246	1248	of
O	1249	1253	mild
O	1254	1256	or
O	1257	1265	moderate
O	1266	1274	severity
O	1275	1278	and
O	1279	1287	occurred
O	1288	1298	relatively
O	1299	1304	early
O	1305	1310	after
O	1311	1320	treatment
O	1321	1331	initiation
O	1332	1333	(
O	1333	1339	except
O	1340	1351	pneumonitis
O	1351	1352	)
O	1352	1353	;
O	1354	1363	incidence
O	1364	1371	tapered
O	1372	1375	off
O	1376	1386	thereafter
O	1386	1387	.

O	1388	1391	EVE
B-outcome	1392	1396	dose
I-outcome	1397	1406	reduction
O	1407	1410	and
B-outcome	1411	1423	interruption
O	1424	1425	(
B-iv-bin-abs	1425	1428	360
O	1429	1432	and
B-iv-bin-abs	1433	1436	705
O	1437	1443	events
O	1443	1444	,
O	1445	1457	respectively
O	1457	1458	)
O	1459	1467	required
O	1468	1471	for
O	1472	1474	AE
O	1475	1485	management
O	1486	1490	were
O	1491	1502	independent
O	1503	1505	of
O	1506	1513	patient
O	1514	1517	age
O	1517	1518	.

O	1519	1522	The
B-outcome	1523	1529	median
I-outcome	1530	1538	duration
I-outcome	1539	1541	of
I-outcome	1542	1546	dose
I-outcome	1547	1559	interruption
O	1560	1563	was
O	1564	1565	7
O	1566	1570	days
O	1570	1571	.

B-outcome	1572	1587	Discontinuation
O	1588	1590	of
O	1591	1595	both
O	1596	1601	study
O	1602	1607	drugs
O	1608	1615	because
O	1616	1618	of
O	1619	1622	AEs
O	1623	1626	was
O	1627	1633	higher
O	1634	1638	with
O	1639	1642	EVE
O	1643	1644	+
O	1645	1648	EXE
O	1649	1650	(
B-iv-bin-percent	1650	1651	9
I-iv-bin-percent	1651	1652	%
O	1652	1653	)
O	1654	1660	versus
O	1661	1664	PBO
O	1665	1666	+
O	1667	1670	EXE
O	1671	1672	(
B-cv-bin-percent	1672	1673	3
I-cv-bin-percent	1673	1674	%
O	1674	1675	)
O	1675	1676	.

O	1677	1681	Most
O	1682	1685	EVE
O	1685	1686	-
O	1686	1696	associated
O	1697	1700	AEs
O	1701	1706	occur
O	1707	1711	soon
O	1712	1717	after
O	1718	1728	initiation
O	1729	1731	of
O	1732	1739	therapy
O	1739	1740	,
O	1741	1744	are
O	1745	1754	typically
O	1755	1757	of
O	1758	1762	mild
O	1763	1765	or
O	1766	1774	moderate
O	1775	1783	severity
O	1783	1784	,
O	1785	1788	and
O	1789	1792	are
O	1793	1802	generally
O	1803	1813	manageable
O	1814	1818	with
O	1819	1823	dose
O	1824	1833	reduction
O	1834	1837	and
O	1838	1850	interruption
O	1850	1851	.

O	1852	1867	Discontinuation
O	1868	1871	due
O	1872	1874	to
O	1875	1883	toxicity
O	1884	1887	was
O	1888	1896	uncommon
O	1896	1897	.

O	1898	1911	Understanding
O	1912	1915	the
O	1916	1920	time
O	1921	1927	course
O	1928	1930	of
O	1931	1936	class
O	1936	1937	-
O	1937	1943	effect
O	1944	1947	AEs
O	1948	1952	will
O	1953	1957	help
O	1958	1964	inform
O	1965	1975	preventive
O	1976	1979	and
O	1980	1990	monitoring
O	1991	2001	strategies
O	2002	2004	as
O	2005	2009	well
O	2010	2012	as
O	2013	2020	patient
O	2021	2030	education
O	2030	2031	.

O	2032	2043	NCT00863655
O	2043	2044	.
